A prospective Phase II study to examine the relationship between quality of life and adverse events of first‐line chemotherapy plus cetuximab in patients with KRAS wild‐type unresectable metastatic colorectal cancer: QUACK trial
暂无分享,去创建一个
M. Ando | Masato Nakamura | J. Sakamoto | S. Morita | Y. Miyake | T. Sudo | Y. Hashiguchi | K. Yamaguchi | A. Tsuji | M. Ishikawa | Y. Kagawa | H. Hara | M. Kotaka | S. Iwamoto | H. Satake | A. Ooki | T. Shingai | H. Tanioka | M. Kataoka | Taichi Yabuno